{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T20:59:24Z","timestamp":1793048364438,"version":"4.5.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T00:00:00Z","timestamp":1688688000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.ejps.2023.106522","type":"journal-article","created":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T21:15:03Z","timestamp":1688764503000},"page":"106522","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Nebulization of PEGylated recombinant human deoxyribonuclease I using vibrating membrane nebulizers: A technical feasibility study"],"prefix":"10.1016","volume":"189","author":[{"given":"Sohaib","family":"Mahri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Wilms","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Hagedorm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Julie","family":"Guichard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Vanvarenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mireille","family":"Dumoulin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henderik","family":"Frijlink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0784-8771","authenticated-orcid":false,"given":"Rita","family":"Vanbever","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ejps.2023.106522_bib0001","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1183\/09031936.00006211","article-title":"Improved treatment response to dornase alfa in cystic fibrosis patients using controlled inhalation","volume":"38","author":"Bakker","year":"2011","journal-title":"Eur. Respir. J."},{"issue":"2","key":"10.1016\/j.ejps.2023.106522_bib0002","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/ppul.22800","article-title":"Small airway deposition of dornase alfa during exacerbations in cystic fibrosis; a randomized controlled clinical trial","volume":"49","author":"Bakker","year":"2014","journal-title":"Pediatr. Pulmonol."},{"issue":"8","key":"10.1016\/j.ejps.2023.106522_bib0003","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1080\/17425247.2018.1503251","article-title":"Designing inhaled protein therapeutics for topical lung delivery: what are the next steps?","volume":"15","author":"Bodier-Montagutelli","year":"2018","journal-title":"Expert. Opin. Drug Deliv."},{"key":"10.1016\/j.ejps.2023.106522_bib0004","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ejpb.2020.04.006","article-title":"Protein stability during nebulization: Mind the collection step!","volume":"152","author":"Bodier-Montagutelli","year":"2020","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"6","key":"10.1016\/j.ejps.2023.106522_bib0005","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/0021-8502(95)00027-A","article-title":"Electrospraying of conducting liquids for monodisperse aerosol generation in the 4 nm to 1.8 \u03bcm diameter range","volume":"26","author":"Chen","year":"1995","journal-title":"J. Aerosol Sci."},{"key":"10.1016\/j.ejps.2023.106522_bib0006","first-page":"50","article-title":"Assessment of aerosol delivery systems for recombinant human deoxyribonuclease","volume":"4","author":"Cipolla","year":"1994","journal-title":"STP Pharma Sci."},{"issue":"3","key":"10.1016\/j.ejps.2023.106522_bib0007","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1110\/ps.34602","article-title":"Single-domain antibody fragments with high conformational stability","volume":"11","author":"Dumoulin","year":"2002","journal-title":"Protein Sci."},{"issue":"4","key":"10.1016\/j.ejps.2023.106522_bib0008","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/s41573-018-0005-0","article-title":"Polymer-drug conjugate therapeutics: advances, insights and prospects","volume":"18","author":"Ekladious","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"issue":"10","key":"10.1016\/j.ejps.2023.106522_bib0009","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1056\/NEJM199409083311003","article-title":"Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group","volume":"331","author":"Fuchs","year":"1994","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.ejps.2023.106522_bib0010","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1021\/bc025561p","article-title":"High temperature biocatalysis by chemically modified cytochrome C","volume":"13","author":"Garc\u00eda-Arellano","year":"2002","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ejps.2023.106522_bib0011","series-title":"Encyclopedia of Biological Chemistry III (Third Edition)","first-page":"105","article-title":"Protein Folding | Protein Folding and Assembly\u2606","author":"Goldenberg","year":"2021"},{"issue":"12","key":"10.1016\/j.ejps.2023.106522_bib0012","first-page":"1419","article-title":"The electrospray and its application to targeted drug inhalation","volume":"47","author":"Gomez","year":"2002","journal-title":"Respir. Care"},{"issue":"1-2","key":"10.1016\/j.ejps.2023.106522_bib0013","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ijpharm.2017.03.057","article-title":"Production and characterization of a PEGylated derivative of recombinant human deoxyribonuclease I for cystic fibrosis therapy","volume":"524","author":"Guichard","year":"2017","journal-title":"Int. J. Pharm."},{"issue":"2","key":"10.1016\/j.ejps.2023.106522_bib0014","doi-asserted-by":"crossref","DOI":"10.1002\/adtp.202000146","article-title":"PEGylation of Recombinant Human Deoxyribonuclease I Provides a Long-Acting Version of the Mucolytic for Patients with Cystic Fibrosis","volume":"4","author":"Guichard","year":"2021","journal-title":"Adv. Therapeut."},{"key":"10.1016\/j.ejps.2023.106522_bib0015","doi-asserted-by":"crossref","first-page":"176","DOI":"10.4103\/2277-9175.164001","article-title":"Stability and biological activity evaluations of PEGylated human basic fibroblast growth factor","volume":"4","author":"Hadadian","year":"2015","journal-title":"Adv. Biomed. Res."},{"key":"10.1016\/j.ejps.2023.106522_bib0016","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.addr.2014.10.003","article-title":"Protein stability in pulmonary drug delivery via nebulization","volume":"93","author":"Hertel","year":"2015","journal-title":"Adv. Drug. Deliv. Rev."},{"issue":"6","key":"10.1016\/j.ejps.2023.106522_bib0017","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1152\/jappl.2001.91.6.2735","article-title":"Electro-hydrodynamic atomization of drug solutions for inhalation purposes","volume":"91","author":"Ijsebaert","year":"2001","journal-title":"J. Appl. Physiol. (1985)"},{"issue":"7","key":"10.1016\/j.ejps.2023.106522_bib0018","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1021\/bm2005017","article-title":"Helix Stabilization of Poly(ethylene glycol)\u2013Peptide Conjugates","volume":"12","author":"Jain","year":"2011","journal-title":"Biomacromolecules"},{"issue":"12","key":"10.1016\/j.ejps.2023.106522_bib0019","first-page":"1703","article-title":"Aerosol delivery of recombinant human DNase I: in vitro comparison of a vibrating-mesh nebulizer with a jet nebulizer","volume":"53","author":"Johnson","year":"2008","journal-title":"Respir. Care"},{"key":"10.1016\/j.ejps.2023.106522_bib0020","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jaerosci.2018.04.009","article-title":"Electrospray deposition of biomolecules: Applications, challenges, and recommendations","volume":"125","author":"Kavadiya","year":"2018","journal-title":"J. Aerosol Sci."},{"issue":"5","key":"10.1016\/j.ejps.2023.106522_bib0021","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1136\/thorax.57.5.459","article-title":"Determinants of adherence in adults with cystic fibrosis","volume":"57","author":"Kettler","year":"2002","journal-title":"Thorax"},{"issue":"9","key":"10.1016\/j.ejps.2023.106522_bib0022","doi-asserted-by":"crossref","first-page":"e4392","DOI":"10.1002\/pro.4392","article-title":"Impact of the PEG length and PEGylation site on the structural, thermodynamic, thermal, and proteolytic stability of mono-PEGylated alpha-1 antitrypsin","volume":"31","author":"Liu","year":"2022","journal-title":"Protein Sci."},{"key":"10.1016\/j.ejps.2023.106522_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.121355","article-title":"Production and characterization of mono-PEGylated alpha-1 antitrypsin for augmentation therapy","volume":"612","author":"Liu","year":"2022","journal-title":"Int. J. Pharm."},{"issue":"15","key":"10.1016\/j.ejps.2023.106522_bib0024","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.clinbiochem.2012.05.034","article-title":"Cystic fibrosis: insight into CFTR pathophysiology and pharmacotherapy","volume":"45","author":"Lubamba","year":"2012","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.ejps.2023.106522_bib0025","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.jconrel.2020.10.034","article-title":"Biodistribution and elimination pathways of PEGylated recombinant human deoxyribonuclease I after pulmonary delivery in mice","volume":"329","author":"Mahri","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejps.2023.106522_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.120107","article-title":"PEGylation of recombinant human deoxyribonuclease I decreases its transport across lung epithelial cells and uptake by macrophages","volume":"593","author":"Mahri","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2023.106522_bib0027","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/j.jconrel.2020.10.046","article-title":"Protein encapsulation by electrospinning and electrospraying","volume":"329","author":"Moreira","year":"2021","journal-title":"J. Control. Release"},{"issue":"6","key":"10.1016\/j.ejps.2023.106522_bib0028","doi-asserted-by":"crossref","first-page":"801","DOI":"10.3111\/13696998.2013.787427","article-title":"Adherence to dornase alfa treatment among commercially insured patients with cystic fibrosis","volume":"16","author":"Nasr","year":"2013","journal-title":"J. Med. Econ."},{"key":"10.1016\/j.ejps.2023.106522_bib0029","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/0378-5173(94)90117-1","article-title":"Protein nebulization: I. Stability of lactate dehydrogenase and recombinant granulocyte-colony stimulating factor to air-jet nebulization","volume":"109","author":"Niven","year":"1994","journal-title":"Int. J. Pharma."},{"issue":"1","key":"10.1016\/j.ejps.2023.106522_bib0030","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1023\/A:1016282502954","article-title":"Some factors associated with the ultrasonic nebulization of proteins","volume":"12","author":"Niven","year":"1995","journal-title":"Pharm. Res."},{"issue":"2","key":"10.1016\/j.ejps.2023.106522_bib0031","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/0378-5173(95)04209-1","article-title":"Protein nebulization II. Stabilization of G-CSF to air-jet nebulization and the role of protectants","volume":"127","author":"Niven","year":"1996","journal-title":"Int. J. Pharma."},{"key":"10.1016\/j.ejps.2023.106522_bib0032","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0076-6879(72)26005-0","article-title":"The preparation of guanidine hydrochloride","volume":"26","author":"Nozaki","year":"1972","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.ejps.2023.106522_bib0033","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1098\/rstb.2004.1500","article-title":"Protein structure, stability and solubility in water and other solvents","volume":"359","author":"Pace","year":"2004","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"issue":"10","key":"10.1016\/j.ejps.2023.106522_bib0034","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s10856-005-4426-z","article-title":"Electrohydrodynamic atomization of protein (bovine serum albumin)","volume":"16","author":"Pareta","year":"2005","journal-title":"J. Mater. Sci. Mater. Med."},{"issue":"2","key":"10.1016\/j.ejps.2023.106522_bib0035","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.ejpb.2011.05.003","article-title":"Effects of PEG size on structure, function and stability of PEGylated BSA","volume":"79","author":"Plesner","year":"2011","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejps.2023.106522_bib0036","unstructured":"Preparation for nebulisation: Characterization, in 2.9.44, EuropeanPharmacopoeia, Editor. 2012."},{"issue":"11","key":"10.1016\/j.ejps.2023.106522_bib0037","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1021\/cb200277u","article-title":"N-PEGylation of a reverse turn is stabilizing in multiple sequence contexts, unlike N-GlcNAcylation","volume":"6","author":"Price","year":"2011","journal-title":"ACS Chem. Biol."},{"issue":"5","key":"10.1016\/j.ejps.2023.106522_bib0038","doi-asserted-by":"crossref","first-page":"595","DOI":"10.4187\/aarc0427","article-title":"Cystic fibrosis: pathogenesis and future treatment strategies","volume":"54","author":"Ratjen","year":"2009","journal-title":"Respir. Care"},{"issue":"5","key":"10.1016\/j.ejps.2023.106522_bib0039","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.4161\/mabs.29938","article-title":"Effect of formulation on the stability and aerosol performance of a nebulized antibody","volume":"6","author":"Respaud","year":"2014","journal-title":"mAbs"},{"key":"10.1016\/j.ejps.2023.106522_bib0040","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jconrel.2016.05.018","article-title":"Development of a drug delivery system for efficient alveolar delivery of a neutralizing monoclonal antibody to treat pulmonary intoxication to ricin","volume":"234","author":"Respaud","year":"2016","journal-title":"J. Control. Release"},{"issue":"6","key":"10.1016\/j.ejps.2023.106522_bib0041","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1002\/bit.22014","article-title":"Stabilization of alpha-chymotrypsin upon PEGylation correlates with reduced structural dynamics","volume":"101","author":"Rodr\u00edguez-Mart\u00ednez","year":"2008","journal-title":"Biotechnol. Bioeng."},{"issue":"6","key":"10.1016\/j.ejps.2023.106522_bib0042","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1111\/j.2042-7158.2011.01288.x","article-title":"Prevention of benzyl alcohol-induced aggregation of chymotrypsinogen by PEGylation","volume":"63","author":"Rodr\u00edguez-Mart\u00ednez","year":"2011","journal-title":"J. Pharm. Pharmacol."},{"issue":"44","key":"10.1016\/j.ejps.2023.106522_bib0043","doi-asserted-by":"crossref","DOI":"10.1002\/adfm.202101633","article-title":"Protein Engineering Strategies for Improved Pharmacokinetics","volume":"31","author":"Rondon","year":"2021","journal-title":"Adv. Funct. Mater."},{"issue":"1","key":"10.1016\/j.ejps.2023.106522_bib0045","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/jps.22231","article-title":"A technical feasibility study of dornase alfa delivery with eFlow(R) vibrating membrane nebulizers: aerosol characteristics and physicochemical stability","volume":"100","author":"Scherer","year":"2011","journal-title":"J. Pharm. Sci."},{"issue":"2","key":"10.1016\/j.ejps.2023.106522_bib0046","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1006\/abio.1994.1502","article-title":"Colorimetric determination of DNase I activity with a DNA-methyl green substrate","volume":"222","author":"Sinicropi","year":"1994","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.ejps.2023.106522_bib0047","series-title":"Aerosol Particle Size Characterization of Several Common Respiratory Formulations from a Novel Handheld Mesh Nebulizer","author":"Slator","year":"2017"},{"issue":"1","key":"10.1016\/j.ejps.2023.106522_bib0048","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.xphs.2018.10.045","article-title":"Steric Repulsion Forces Contributed by PEGylation of Interleukin-1 Receptor Antagonist Reduce Gelation and Aggregation at the Silicone Oil-Water Interface","volume":"108","author":"Sorret","year":"2019","journal-title":"J. Pharm. Sci."},{"issue":"3","key":"10.1016\/j.ejps.2023.106522_bib0049","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2165\/00063030-200519030-00001","article-title":"The use of human deoxyribonuclease (rhDNase) in the management of cystic fibrosis","volume":"19","author":"Suri","year":"2005","journal-title":"BioDrugs"},{"issue":"1","key":"10.1016\/j.ejps.2023.106522_bib0051","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s12931-019-1057-3","article-title":"Topical application of nebulized human IgG, IgA and IgAM in the lungs of rats and non-human primates","volume":"20","author":"Vonarburg","year":"2019","journal-title":"Respir. Res."},{"key":"10.1016\/j.ejps.2023.106522_bib0052","article-title":"Electrospraying: Possibilities and Challenges of Engineering Carriers for Biomedical Applications\u2014A Mini Review","volume":"7","author":"Wang","year":"2019","journal-title":"Front. Chem."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098723001525?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098723001525?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T12:07:31Z","timestamp":1760530051000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098723001525"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":50,"alternative-id":["S0928098723001525"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2023.106522","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nebulization of PEGylated recombinant human deoxyribonuclease I using vibrating membrane nebulizers: A technical feasibility study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2023.106522","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106522"}}